Drug intelligence / Profile preview

atropine + fentanyl

Development stage
Phase 4
Lead developer
Johnson & Johnson
Modality
Small Molecules
Administration
Intramuscular, Intravenous, Subcutaneous
01

Overview

Atropine + fentanyl is a combination of two pharmaceutical agents commonly used in anesthesia and perioperative care. Atropine is an antimuscarinic agent that blocks the action of acetylcholine at muscarinic receptors in the parasympathetic nervous system. It is primarily used to reduce secretions and prevent bradycardia during surgical procedures. Fentanyl is a potent synthetic opioid analgesic that acts as an agonist at mu-opioid receptors in the central nervous system to provide profound pain relief and sedation. The combination may be used for premedication before anesthesia or for procedural sedation; atropine helps counteract opioid-induced bradycardia while fentanyl provides analgesia[1][2][5]. Both drugs are well-established pharmaceuticals with broad use in clinical practice.

Brand names
IonsysAPO-fentaYNL MatrixCO fentaYNLMylan-fentaNYL Matrix PatchRan-fentaYNL MatrixRan-fentaYNL Transdermal System 100Ran-fentaYNL Transdermal System 25Ran-fentaYNL Transdermal System 50Ran-fentaYNL Transdermal System 75Sandoz fentaNYL PatchTeva fentaNYL 100Teva fentaNYL 12
02

Targets

DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)mAChR (Muscarinic acetylcholine receptors)

Beyond the preview

Go deeper on atropine + fentanyl.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on atropine + fentanyl.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call